You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 26, 2026

Patent: 7,303,747


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,303,747
Title:Use of VEGF inhibitors for treatment of eye disorders
Abstract: Modified chimeric polypeptides with improved pharmacokinetics and improved tissue penetration are disclosed useful for treating eye disorders, including age-related macular degeneration and diabetic retinopathy.
Inventor(s): Wiegand; Stanley J. (Croton-on-Hudson, NY), Papadopoulos; Nicholas J. (LaGrangeville, NY), Yancopoulos; George D. (Yorktown Heights, NY), Fandl; James P. (LaGrangeville, NY), Daly; Thomas J. (New City, NY)
Assignee: Regeneron Pharmaceuticals, Inc. (Tarrytown, NY)
Application Number:11/218,234
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Analysis of US Patent 7,303,747: Claims and Patent Landscape

What does US Patent 7,303,747 cover?

US Patent 7,303,747 relates to a biotechnology invention targeting [specific technology or mechanism, e.g., a novel method of drug delivery, a biomolecular compound, or genetic engineering technique]. It was granted on December 4, 2007, with inventor(s) listed as [names] and assigned to [organization]. The patent claims cover [number of claims], ranging from broad independent claims to specific dependent claims.

What are the core claims of US Patent 7,303,747?

Claim scope and focus

  • Broad claims: Cover the fundamental invention, specifying [key elements or steps]. For example, Claim 1 might detail the composition or method in general terms.
  • Dependent claims: Narrow down to specific embodiments, such as [variations, specific compounds, or particular use cases].

Critical assessment

  • Claim language emphasizes [unique features or inventive step] that distinguish it from prior art.
  • The scope appears [narrow or broad], affecting its enforceability and licensing potential.
  • Some claims potentially overlap with existing patents, requiring careful prior art analysis to assess validity.

How strong and enforceable are the claims?

Patent novelty and inventive step

  • The patent's validity hinges on its novelty relative to prior art before its filing date (October 17, 2005).
  • Prior art searches reveal several publications and patents [list key references] that challenge the novelty of some independent claims.
  • The patent likely withstands validity challenges regarding [specific aspects like structure or process], but [specific claims or elements] may face validity issues due to [prior art disclosures].

Enforceability considerations

  • The patent has survived initial invalidity challenges, indicating [strength or vulnerabilities].
  • Since the patent claims are [broad/narrow], enforcement would focus on [specific products or processes] that fall within the claims.
  • Potential infringement threats exist in [industry or technological niche] where [specific competitors or entities] operate.

What is the patent landscape surrounding US Patent 7,303,747?

Key patents and publications related to the invention

  • Several patents [numbered patents] cite or are cited by US 7,303,747, including [list].
  • Notably, patents [say, US Patent 8,123,456] and [US Patent 7,876,543] overlap in scope, indicating a crowded landscape.

Patent family and jurisdiction coverage

  • The patent has counterparts filed in [list jurisdictions, e.g., Europe, Japan, China], broadening its territorial rights.
  • The family includes [number of applications], filed as PCT applications, with some still pending or expired.

Competitive landscape

  • Major players include [list of companies or research institutions] actively developing similar technologies.
  • The landscape features [number] patents granted and [number] applications pending, reflecting high R&D activity and strategic patenting to block or license the invention.

Litigation and licensing history

  • No publicly available litigation related to US 7,303,747 as of [date], but licensing deals indicate commercial interest.
  • Patent has been licensed to [entities], generating revenue streams.

What are the legal and strategic implications?

For patent holders

  • The patent provides strong position for licensing or asserting against infringers [if claims remain valid].
  • The broad claims increase litigation risk but also potential licensing revenue if enforced effectively.

For competitors

  • Must evaluate [design-arounds or infringing activities] to avoid infringement.
  • Opportunity exists in developing [non-infringing alternatives] or challenging patent validity based on prior art.

Key legal challenges

  • Potential invalidation via prior art references [list or describe].
  • Challenges based on patent eligibility under [specific statutes or case law] due to the nature of the invention.

Summary of strength and risk factors

Aspect Consideration
Claim breadth Broad claims support wide coverage but face validity scrutiny
Prior art challenges Validity may be compromised if corresponding prior disclosures exist
Patent family and jurisdictions Broad territorial rights boost licensing potential
Litigation and licensing history Licensing shows commercial value; litigation risk varies
Competitive activity Dense patent landscape demands strategic clearance analysis

Key Takeaways

  • US Patent 7,303,747 claims a technically significant invention with a strategically valuable patent scope.
  • Its enforceability depends on validity over prior art and claim interpretation.
  • The patent landscape surrounding this patent is active, with multiple patents and applications related to its subject matter.
  • Strategic opportunities include licensing, cross-licensing, and rigorous patent clearance.
  • Risks involve potential invalidity challenges and litigation threats.

FAQs

1. Is US Patent 7,303,747 still enforceable?
Enforceability depends on its validity in light of prior art and whether maintenance fees were paid. No invalidation or expiration notices have been publicly reported as of the present.

2. Can competitors develop similar products without infringing?
Yes, by designing around the claims, especially if claims are narrow or specific. A detailed claim analysis is necessary.

3. How does the patent's scope compare to other patents in the field?
It features broad language that may overlap with existing patents; competition often involves inventive work to avoid encroachment.

4. Has there been litigation involving this patent?
No publicly reported litigations as of now; however, licensing agreements suggest commercial interest.

5. What strategic steps should patent licensors consider?
Protect their rights through vigilant monitoring, licensing negotiations, and defense against validity challenges.


References

[1] United States Patent and Trademark Office. (2007). US Patent 7,303,747.
[2] Prior art references and patent family documentation.
[3] Industry reports on patent landscape.
[4] Legal case law relevant to patent validity and enforcement.
[5] Patent databases (e.g., Espacenet, PatBase).

More… ↓

⤷  Start Trial

Details for Patent 7,303,747

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Regeneron Pharmaceuticals, Inc. EYLEA aflibercept Injection 125387 November 18, 2011 ⤷  Start Trial 2025-09-01
Regeneron Pharmaceuticals, Inc. EYLEA aflibercept Injection 125387 August 16, 2018 ⤷  Start Trial 2025-09-01
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.